"label","id","uuid:ID","name","instanceType","text","description"
"","Objective_1","85c081a3-487f-4ac0-89a2-151cdff6c9cb","OBJ1","OBJECTIVE","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Main objective"
"","Objective_2","96d51465-0f77-4e34-88a4-5fdf6ed119f5","OBJ2","OBJECTIVE","To document the safety profile of the xanomeline TTS.","Safety"
"","Objective_3","4e1eb40e-5d31-42c8-bada-595f8c2d0ea6","OBJ3","OBJECTIVE","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Behaviour"
